Cadrenal Therapeutics' SEC filings document the regulatory record of a Nasdaq-listed, emerging-growth biopharmaceutical company focused on immune, thrombotic, and anticoagulation-related disorders. Its 8-K reports disclose financial results, Regulation FD updates, clinical and regulatory events for CAD-1005, and scientific research involving 12-lipoxygenase inhibition.
The filings also cover capital-structure activity, including common-stock registrations, at-the-market offering materials, registered direct offerings, private-placement warrants, and related material agreements. Company disclosures identify its Delaware corporate status, Nasdaq Capital Market common stock listing, governance status as an emerging growth company, and formal reporting of pipeline developments involving CAD-1005, tecarfarin, and frunexian.
Cadrenal Therapeutics, Inc. (CVKD) common stock is the subject of Investor Ben Baggett’s reported beneficial ownership of 300,000 shares, or 7.3% of the class. He reported sole voting and dispositive power over 300,000 shares, with zero shared power in either category.
Cadrenal Therapeutics, Inc. (CVKD) reported a net loss of $7.1 million for the nine months ended September 30, 2026, compared with $10.2 million a year earlier; cash used in operations was $7.2 million. Cash and cash equivalents were $3.1 million at September 30, 2026, and accumulated deficit was $46.0 million. Cadrenal said its existing cash resources would not cover operating and capital needs for the next 12 months, raising substantial doubt about its ability to continue as a going concern for at least one year after the statements were issued.
On October 7, 2026, the board began a strategic review and retained Tungsten Advisors as its exclusive strategic financial advisor. Options include asset licensing or sales, partnerships, portfolio transactions, a business combination or reverse merger; no definitive transaction is assured. Cadrenal and the FDA aligned on key protocol and Statistical Analysis Plan aspects for a Phase 3 registrational study of CAD-1005 in HIT. Cadrenal said it has not raised enough to complete any clinical trial and will not commence one unless it believes it has sufficient funding to complete it. As of early November 2026, Cadrenal reported a cash position of $2.7 million and believed it could meet immediate operating needs through the first quarter of 2027.
Cadrenal Therapeutics, Inc. Chairman and CEO Quang X. Pham received a direct award of 200,000 stock options on October 9, 2026, under the 2022 Successor Equity Incentive Plan. The options were fully vested and immediately exercisable on the grant date. Their $0.91 exercise price equaled the common stock’s closing price on October 9, 2026, and they expire October 8, 2036. The reported post-transaction position was 200,000 options.
Cadrenal Therapeutics, Inc. director Lee Scott Golden was granted 75,000 stock options on October 9, 2026, under the company’s 2022 Successor Equity Incentive Plan. The options were fully vested and immediately exercisable on the grant date, with an exercise price of $0.91 per share and an expiration date of October 8, 2036. They cover 75,000 shares of common stock, and the exercise price equaled the closing price of the company’s common stock on the grant date.
Cadrenal Therapeutics, Inc. director John Raymond Murphy received a grant of 75,000 stock options on October 9, 2026, covering 75,000 common shares. The options were fully vested and immediately exercisable on the grant date, with a $0.91 exercise price and an expiration date of October 8, 2036.
Cadrenal Therapeutics, Inc. (CVKD) reported that Chief Operating Officer Jeffrey Scott Cole received a grant of 150,000 stock options on October 9, 2026, under the company's 2022 Successor Equity Incentive Plan. The options are reported as directly held and relate to 150,000 shares of common stock.
Cadrenal Therapeutics, Inc. director Glynn Wilson acquired 75,000 stock options on October 9, 2026. The options were fully vested and immediately exercisable on the grant date, carried a $0.91 exercise price, and expire October 8, 2036.
Cadrenal Therapeutics, Inc. (CVKD) says its Board has initiated a formal strategic process to evaluate opportunities involving the company and its asset portfolio. The review may consider licensing or sales of individual assets, development and commercialization partnerships, portfolio transactions, business combinations or other strategic transactions. The programs identified include CAD-1005, tecarfarin, frunexian and CAD-2000. Cadrenal engaged Tungsten Advisors as its exclusive strategic financial advisor and says it has received strong interest from potential strategic partners. The company also reports recent alignment with the FDA on a Phase 3 development pathway for CAD-1005. The review is preliminary; Cadrenal has set no deadline or definitive timetable and says there is no assurance the process will result in a transaction or other strategic outcome.
Cadrenal Therapeutics, Inc. (CVKD) reported that stockholders approved an amendment increasing shares available for awards under the 2022 Successor Equity Incentive Plan by 323,542 shares to 1,000,000 shares. They also approved issuance of up to 960,000 common shares upon exercise of Series C-1 warrants issued in a private placement that closed July 1, 2026.
Quang X. Pham was elected a Class I director to serve until the 2029 annual meeting, and stockholders ratified WithumSmith+Brown, P.C. as the independent registered public accounting firm for fiscal 2026. Although an adjournment proposal passed, the meeting did not need to adjourn because the plan amendment and warrant proposals received the votes required for approval. As of July 27, 2026, 3,567,592 common shares were outstanding and entitled to vote; 2,155,341 shares were represented at the meeting.
Cadrenal Therapeutics, Inc. (CVKD) reported that the FDA provided positive feedback in a Type D Meeting held on July 28, 2026, aligning with the company on key elements of the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005 in heparin-induced thrombocytopenia (HIT).
The FDA agreed to an optimized definition of worsening HIT for the composite primary endpoint, focusing on progression of thrombotic events or hospital discharge through Day 14, including extension of existing thrombi into new vascular segments. The agency also agreed to a placebo-controlled design, with both CAD-1005 and placebo arms receiving standard anticoagulation, and to assess bleeding using International Society on Thrombosis and Haemostasis criteria. Cadrenal highlights HIT as a ~50,000 patient acute market in the U.S. and cites a projected $2 billion peak annual revenue opportunity for CAD-1005.